FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Mastrangelo

Research Profile

Disorders

Chemicals & Drugs

Procedures

Co-author Network

Publications

TOP 3
Amit Mahipal; Michael J Mastrangelo; Kathryn Chan; MaryAnn Laudadio; Lukman Tijani; Takami Sato
A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
Amit Mahipal; Michael J Mastrangelo; Kashyap Patel; David Berd; Inna Chervoneva; Mizue Terai; Takami Sato
Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.
Fred M Kaplan; Michael J Mastrangelo; Andrew E Aplin
The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Mastrangelo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Amit Mahipal; Michael J Mastrangelo; Kathryn Chan; MaryAnn Laudadio; Lukman Tijani; Takami Sato
A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
Melanoma research 2012;22(6):440-6.
2011: Amit Mahipal; Michael J Mastrangelo; Kashyap Patel; David Berd; Inna Chervoneva; Mizue Terai; Takami Sato
Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine.
Cancer immunology, immunotherapy : CII 2011;60(7):1039-45.
2010: Fred M Kaplan; Michael J Mastrangelo; Andrew E Aplin
The wrath of RAFs: rogue behavior of B-RAF kinase inhibitors.
The Journal of investigative dermatology 2010;130(11):2669-71.
2010: Joshua A Marks; Atul S Rao; David Loren; Agnes Witkiewicz; Michael J Mastrangelo; Adam C Berger
Malignant melanoma presenting as obstructive jaundice secondary to metastasis to the Ampulla of Vater.
JOP : Journal of the pancreas 2010;11(2):173-5.
2009: Mizue Terai; Yutaka Tamura; Vitali Alexeev; Eiko Ohtsuka; David Berd; Michael J Mastrangelo; Takami Sato
Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential.
Cancer immunology, immunotherapy : CII 2009;58(8):1307-17.
2009: Akira Yamamoto; Inna Chervoneva; Kevin L Sullivan; David J Eschelman; Carin F Gonsalves; Michael J Mastrangelo; David Berd; Jerry A Shields; Carol L Shields; Mizue Terai; Takami Sato
High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.
Radiology 2009;252(1):290-8.
2008: Takami Sato; David J Eschelman; Carin F Gonsalves; Mizue Terai; Inna Chervoneva; Peter A McCue; Jerry A Shields; Carol L Shields; Akira Yamamoto; David Berd; Michael J Mastrangelo; Kevin L Sullivan
Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5436-42.
2008: Mary K Samplaski; Ernest L Rosato; Agnes Witkiewicz; Michael J Mastrangelo; Adam C Berger
Malignant melanoma of the gallbladder: a report of two cases and review of the literature.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2008;12(6):1123-6.
2007: Tania Mucci; William Long; Agnes Witkiewicz; Michael J Mastrangelo; Ernest L Rosato; Adam C Berger
Metastatic melanoma causing jejunal intussusception.
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2007;11(12):1755-7.
2007: Magdolna Solti; David Berd; Michael J Mastrangelo; Takami Sato
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
Melanoma research 2007;17(4):225-31.
2005: David Berd; Michael J Mastrangelo; Takami Sato
Calculation of survival of patients with stage III melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9427; author reply 9428.
2005: Kashyap Patel; Kevin Sullivan; David Berd; Michael J Mastrangelo; Carol L Shields; Jerry A Shields; Takami Sato
Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.
Melanoma research 2005;15(4):297-304.
2004: David Berd; Takami Sato; Henry C Maguire; John C. Kairys; Michael J Mastrangelo
Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):403-15.
2004: Takami Sato; Mizue Terai; Rie Yasuda; Ryuko Watanabe; David Berd; Michael J Mastrangelo; Kenichiro Hasumi
Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy.
Cancer immunology, immunotherapy : CII 2004;53(1):53-61.
2002: Michael J Mastrangelo; Edmund C Lattime
Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.
Cancer gene therapy 2002;9(12):1013-21.
2002: Jayanthi Manne; Michael J Mastrangelo; Takami Sato; David Berd
TCR rearrangement in lymphocytes infiltrating melanoma metastases after administration of autologous dinitrophenyl-modified vaccine.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(6):3407-12.
2002: David Berd; Takami Sato; Michael J Mastrangelo
Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
Cancer immunology, immunotherapy : CII 2002;51(6):320-6.
2001: David Berd; Takami Sato; Herbert E Cohn; Henry C Maguire; Michael J Mastrangelo
Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
International journal of cancer. Journal international du cancer 2001;94(4):531-9.
2001: Leonard G Gomella; Michael J Mastrangelo; Peter McCue; J R Maguire HC; SG Mulholland; Edmund C Lattime
Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer.
The Journal of urology 2001;166(4):1291-5.
2000: Takekazu Aoyama; Michael J Mastrangelo; David Berd; FE Nathan; Carol L Shields; Jerry A Shields; Ernest L Rosato; Francis E Rosato; Takami Sato
Protracted survival after resection of metastatic uveal melanoma.
Cancer 2000;89(7):1561-8.
2000: Michael J Mastrangelo; Laurence C Eisenlohr; Leonard G Gomella; Edmund C Lattime
Poxvirus vectors: orphaned and underappreciated.
The Journal of clinical investigation 2000;105(8):1031-4.
2000: Michael J Mastrangelo; Henry C Maguire; Edmund C Lattime
Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma.
Advances in experimental medicine and biology 2000;465():391-400.
2000: FE Nathan; David Berd; Takami Sato; Michael J Mastrangelo
Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma.
Cancer 2000;88(1):79-87.
1999: Michael J Mastrangelo; Henry C Maguire; Laurence C Eisenlohr; C E Laughlin; Claude E Monken; Peter McCue; Albert J Kovatich; Edmund C Lattime
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma.
Cancer gene therapy 1999;6(5):409-22.
1999: D T Harris; Gary R Matyas; L G Gomella; EYAL TALOR; MD Winship; LE Spitler; Michael J Mastrangelo
Immunologic approaches to the treatment of prostate cancer.
Seminars in oncology 1999;26(4):439-47.
1998: David Berd; John C. Kairys; Charles J Dunton; Michael J Mastrangelo; Takami Sato; Henry C Maguire
Autologous, hapten-modified vaccine as a treatment for human cancers.
Seminars in oncology 1998;25(6):646-53.
1998: K K Bass; Michael J Mastrangelo
Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer.
Cancer immunology, immunotherapy : CII 1998;47(1):1-12.
1998: FE Nathan; Michael J Mastrangelo
Systemic therapy in melanoma.
Seminars in surgical oncology 1998;14(4):319-27.
1998: Henry C Maguire; David Berd; Edmund C Lattime; Peter McCue; S Kim; Paul B Chapman; Michael J Mastrangelo
Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters.
Cancer biotherapy & radiopharmaceuticals 1998;13(1):13-23.
1998: E F McClay; David Berd; Michael J Mastrangelo
The Dartmouth Regimen: gone or going strong?
Cancer investigation 1998;16(6):421-3.
1998: Michael J Mastrangelo; Takami Sato; Edmund C Lattime; Henry C Maguire; David Berd
Cellular vaccine therapies for cancer.
Cancer treatment and research 1998;94():35-50.
1997: Takami Sato; Timothy N J Bullock; Laurence C Eisenlohr; Michael J Mastrangelo; David Berd
Dinitrophenyl-modified autologous melanoma vaccine induces a T cell response to hapten-modified, melanoma peptides.
Clinical immunology and immunopathology 1997;85(3):265-72.
1997: FE Nathan; David Berd; Takami Sato; J A Shield; Carol L Shields; P De Potter; Michael J Mastrangelo
BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
Journal of experimental & clinical cancer research : CR 1997;16(2):201-8.
1997: David Berd; Henry C Maguire; L M Schuchter; R Hamilton; W W Hauck; Takami Sato; Michael J Mastrangelo
Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2359-70.
1997: Takami Sato; A Babazono; Jerry A Shields; Carol L Shields; P De Potter; Michael J Mastrangelo
Time to systemic metastases in patients with posterior uveal melanoma.
Cancer investigation 1997;15(2):98-105.
1996: Michael J Mastrangelo; Henry C Maguire; Takami Sato; FE Nathan; David Berd
Active specific immunization in the treatment of patients with melanoma.
Seminars in oncology 1996;23(6):773-81.
1996: Takami Sato; Peter McCue; K Masuoka; S Salwen; Edmund C Lattime; Michael J Mastrangelo; David Berd
Interleukin 10 production by human melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(8):1383-90.
1996: David Berd; Michael J Mastrangelo; Edmund C Lattime; Takami Sato; Henry C Maguire
Melanoma and vitiligo: immunology's Grecian urn.
Cancer immunology, immunotherapy : CII 1996;42(5):263-7.
1996: Edmund C Lattime; S S Lee; Laurence C Eisenlohr; Michael J Mastrangelo
In situ cytokine gene transfection using vaccinia virus vectors.
Seminars in oncology 1996;23(1):88-100.
1996: Michael J Mastrangelo; David Berd; FE Nathan; Edmund C Lattime
Gene therapy for human cancer: an essay for clinicians.
Seminars in oncology 1996;23(1):4-21.
1995: FE Nathan; Michael J Mastrangelo
Adjuvant therapy for cutaneous melanoma.
Seminars in oncology 1995;22(6):647-61.
1995: Edmund C Lattime; Michael J Mastrangelo; O Bagasra; W Li; David Berd
Expression of cytokine mRNA in human melanoma tissues.
Cancer immunology, immunotherapy : CII 1995;41(3):151-6.
1995: Takami Sato; Henry C Maguire; Michael J Mastrangelo; David Berd
Human immune response to DNP-modified autologous cells after treatment with a DNP-conjugated melanoma vaccine.
Clinical immunology and immunopathology 1995;74(1):35-43.
1994: David Berd; Henry C Maguire; Michael J Mastrangelo; G Murphy
Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine.
Cancer immunology, immunotherapy : CII 1994;39(3):141-7.
1994: S S Lee; Laurence C Eisenlohr; Peter McCue; Michael J Mastrangelo; Edmund C Lattime
Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors.
Cancer research 1994;54(13):3325-8.
1993: David Berd; Henry C Maguire; Michael J Mastrangelo
Treatment of human melanoma with a hapten-modified autologous vaccine.
Annals of the New York Academy of Sciences 1993;690():147-52.
1993: C McLaughlin; Henry C Maguire; Michael J Mastrangelo
Natural history of a superficial spreading melanoma.
International journal of dermatology 1993;32(4):293-6.
1991: David Berd; G Murphy; Henry C Maguire; Michael J Mastrangelo
Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.
Cancer research 1991;51(10):2731-4.
1990: David Berd; Henry C Maguire; Peter McCue; Michael J Mastrangelo
Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(11):1858-67.
1989: David Berd; M Herlyn; Hilary Koprowski; Michael J Mastrangelo
Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens.
Cancer research 1989;49(23):6840-4.
1989: Barbara J Turner; R M Siatkowski; James J Augsburger; Jerry A Shields; E Lustbader; Michael J Mastrangelo
Other cancers in uveal melanoma patients and their families.
American journal of ophthalmology 1989;107(6):601-8.
1988: David Berd; Michael J Mastrangelo
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
Cancer research 1988;48(6):1671-5.
1988: David Berd; Michael J Mastrangelo
Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.
Cancer investigation 1988;6(3):337-49.
1987: David Berd; Michael J Mastrangelo
Elimination of immune suppressor mechanisms in humans by oxazaphosphorines.
Methods and findings in experimental and clinical pharmacology 1987;9(9):569-77.